Clin Trans Gastro: 环氧合酶-2和细胞溶质磷脂酶A2在粘液性胰腺囊肿中过表达

2019-05-20 不详 MedSci原创

前列腺素生物合成途径酶在粘液性胰腺囊肿中的表达尚不清楚。因此,本项研究旨在评估胰腺囊肿上皮中COX-2,细胞溶质磷脂酶A2(cPLA2)和蛋白激酶B(AKT)的表达,以及与阿司匹林(ASA)和囊肿液前列腺素E 2(PGE 2)浓度相关的酶表达关系。

背景及目的:
前列腺素生物合成途径酶在粘液性胰腺囊肿中的表达尚不清楚。因此,本项研究旨在评估胰腺囊肿上皮中COX-2,细胞溶质磷脂酶A2(cPLA2)和蛋白激酶B(AKT)的表达,以及与阿司匹林(ASA)和囊肿液前列腺素E 2(PGE 2)浓度相关的酶表达关系。

方法:
研究人员回顾性分析了80例胰腺囊肿切术术后的病理学特征。通过组织免疫组织化学免疫反应性评分(IRS)定量COX-2,cPLA2和AKT的表达。在囊肿类型和(在30例中)匹配的囊液PGE 2浓度之间比较IRS值。

结果:
对于COX-2来说,粘液性与非粘液性囊肿的上皮细胞的平均IRS较高(6.1±4.7 VS 3.2±2.8,P = 0.01),cPLA2也明显升高(6.9±3.0VS 2.9±2.9,P <0.001)。低级别不典型增生的粘液性囊肿囊肿上皮COX-2表达高于高度异型增生或浸润性癌(IRS 8.0±3.9 vs 1.5±2.9,P <0.001),而cPLA2则相反(6.2±3.0 VS 8.6±2.3,P = 0.005)。

结论:
COX-2和cPLA2在粘液性胰腺囊肿的上皮中过表达。COX-2和/或cPLA2抑制可以防止粘液性胰腺囊肿的出现或进展,但是可能需要更高剂量的ASA或非甾体抗炎药来基本上抑制囊肿上皮COX-2活性。

原始出处:
Mensah, Elsie T. et al. Cyclooxygenase-2 and Cytosolic Phospholipase A2 Are Overexpressed in Mucinous Pancreatic Cysts. Clinical and Translational Gastroenterology. 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2072567, encodeId=385d20e256727, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Mon Mar 16 14:35:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657172, encodeId=e729165e17220, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 15 18:35:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958196, encodeId=95551958196b7, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Thu Jan 02 03:35:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711950, encodeId=a5551e1195031, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri May 01 08:35:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340803, encodeId=6f1e134080310, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Wed May 22 09:35:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604504, encodeId=f3bc1604504a2, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Wed May 22 09:35:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2020-03-16 许安
  2. [GetPortalCommentsPageByObjectIdResponse(id=2072567, encodeId=385d20e256727, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Mon Mar 16 14:35:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657172, encodeId=e729165e17220, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 15 18:35:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958196, encodeId=95551958196b7, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Thu Jan 02 03:35:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711950, encodeId=a5551e1195031, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri May 01 08:35:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340803, encodeId=6f1e134080310, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Wed May 22 09:35:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604504, encodeId=f3bc1604504a2, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Wed May 22 09:35:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2019-09-15 bsmagic9140
  3. [GetPortalCommentsPageByObjectIdResponse(id=2072567, encodeId=385d20e256727, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Mon Mar 16 14:35:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657172, encodeId=e729165e17220, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 15 18:35:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958196, encodeId=95551958196b7, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Thu Jan 02 03:35:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711950, encodeId=a5551e1195031, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri May 01 08:35:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340803, encodeId=6f1e134080310, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Wed May 22 09:35:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604504, encodeId=f3bc1604504a2, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Wed May 22 09:35:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2020-01-02 lq1767
  4. [GetPortalCommentsPageByObjectIdResponse(id=2072567, encodeId=385d20e256727, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Mon Mar 16 14:35:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657172, encodeId=e729165e17220, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 15 18:35:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958196, encodeId=95551958196b7, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Thu Jan 02 03:35:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711950, encodeId=a5551e1195031, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri May 01 08:35:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340803, encodeId=6f1e134080310, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Wed May 22 09:35:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604504, encodeId=f3bc1604504a2, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Wed May 22 09:35:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2072567, encodeId=385d20e256727, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Mon Mar 16 14:35:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657172, encodeId=e729165e17220, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 15 18:35:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958196, encodeId=95551958196b7, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Thu Jan 02 03:35:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711950, encodeId=a5551e1195031, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri May 01 08:35:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340803, encodeId=6f1e134080310, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Wed May 22 09:35:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604504, encodeId=f3bc1604504a2, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Wed May 22 09:35:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2072567, encodeId=385d20e256727, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Mon Mar 16 14:35:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657172, encodeId=e729165e17220, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun Sep 15 18:35:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958196, encodeId=95551958196b7, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Thu Jan 02 03:35:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711950, encodeId=a5551e1195031, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri May 01 08:35:00 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340803, encodeId=6f1e134080310, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Wed May 22 09:35:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604504, encodeId=f3bc1604504a2, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Wed May 22 09:35:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]

相关资讯

Cancer Res:西乐葆有助于抑制肿瘤细胞生长

科学家们发现常用疼痛药物可抑制肿瘤细胞的进展。他们认为西乐葆(一种常用止痛药和抗炎药)可减缓某种肿瘤的进程。研究发表在Cancer Research。 在一个实验动物模型中,佛罗里达斯克里普斯研究所的研究人员发现,西乐葆可减缓II型神经纤维瘤(NF2)患者癌细胞的生长速率。他们认为,该药物对其他类型的肿瘤细胞或许有相似的效果。 西乐葆是一种非甾体类抗炎药(NSAID),主要用途是治疗关节炎和强直性

PNAS:新药物分子成功抑制肿瘤生长和转移

加州大学戴维斯分校,马萨诸塞大学和哈佛医学院研究人员成功将COX-2抑制剂如Celebrex与一个环氧化物水解酶(sEH)抑制剂组合起来,创建出一个新的潜在药物分子(PTUTB),此新药物能同时抑制肿瘤的生长和转移。通过将COX-2抑制剂和一个环氧化物水解酶(sEH)抑制剂组合,该药物PTUTB能控制血管生成(血管形成),限制了肿瘤的生长和扩散的能力。这项研究发表在PNAS杂志上。 加

J Natl Cancer Inst:肺癌治疗的独特选择:解析COX-2抑制剂的应用

COX-2介导包括PGE-2在内的前列腺素的合成,其将炎症和细胞分裂信号相联系,它同时也是一个抗肿瘤治疗靶点,但由于以往研究数据的不可靠性和肿瘤对COX-2抑制剂反应的不一致性,针对COX-2的治疗一直受限制。 研究分析了癌症基因图谱(TCGA)和指导者挑战(Dircter’s Challenge)肺癌数据库(n=188),并通过搜索C-MAP数据库形成了一个无LKB-1表达的癌症基因标签(n=

Cancer Res:COX-2抑制剂塞来昔布可能具有抗癌作用

最近,美国斯克里普斯研究所(TSRI)佛罗里达校区的科学家发现,一种最广泛使用的止痛、抗炎药物,可在动物模型中减缓一种特殊肿瘤的增长速度,并指出这种药物可能对其他类型的肿瘤也有相同的作用。这项新研究在Cancer Research杂志,关注的是塞来昔布的抗癌作用。塞来昔布可靶定一个称为“cyclooxygenase-2”(COX-2)的酶,这个酶与疼痛和炎症有关联。这种酶对于前列腺素的产生也很重要

J Endod:尖周损伤的环氧化酶2和肿瘤坏死因子α的检测

这篇研究的目的是为了评估根尖周肉芽肿(PG)和根尖周囊肿(RC)样本中环氧化酶2(COX-2)和肿瘤坏死因子α (TNF-α)的表达以及其与损伤类型、炎症浸润的程度和上皮层厚度之间的关系。

J Invest Derm:非甾体类抗炎药(NSAIDs)可能预防皮肤癌

据一项最新研究表明非甾体类抗炎药(NSAIDs)能够预防皮肤癌,该研究发表于近日的Journal of Investigative Dermatology上。NSAID可以降低大肠癌、肺癌、乳腺癌和前列腺癌的发病风险,但是还没有证据表明它能够预防皮肤癌。Chiho Muranushi及其同事根据已发表的文献进行了meta分析,研究了阿司匹林、非阿司匹林类NSAIDs以及其他NSAIDs类药物对鳞状